Posted by Michael Wonder on 12 Jan 2021
Health Canada approves Bavencio for the maintenance treatment of patients with advanced bladder cancer
11 January 2021 - Bavencio is the first and only maintenance therapy for unresectable locally advanced or metastatic urothelial carcinoma approved by Health Canada
EMD Serono Canada and Pfizer Canada ULC announced that Health Canada has approved Bavencio (avelumab) for the maintenance treatment of patients with unresectable locally advanced or metastatic urothelial carcinoma whose disease has not progressed following first-line platinum-based chemotherapy.
